M. Sue Kirkman

M. Sue Kirkman

Auto-generated profile, based on publicly available information

M. Sue Kirkman

University of North Carolina School of Medicine, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
RHRichard I.G. Holt
Richard I.G. Holt
JDJ. Hans DeVries
J. Hans DeVries
AHAmy Hess-Fischl
Amy Hess-Fischl
IHIrl B. Hirsch
Irl B. Hirsch
MKM. Sue Kirkman
M. Sue Kirkman
APAnne Peters
Anne Peters
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a writing group to develop a consensus statement on the management of type 1 diabetes in adults. The writing group has considered the rapid development of new treatments and technologies and addressed the following topics: diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycemia, behavioral considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management, and future perspectives. Although we discuss the schedule for follow-up examinations and testing, we have not included the evaluation and treatment of the chronic microvascular and macrovascular complications of diabetes as these are well-reviewed and discussed elsewhere. The writing group was aware of both national and international guidance on type 1 diabetes and did not seek to replicate this but rather aimed to highlight the major areas that health care professionals should consider when managing adults with type 1 diabetes. Though evidence-based where possible, the recommendations in the report represent the consensus opinion of the authors.

20 July 2023 in Diabetes Care
Verified
Journal Article
Open access
PDF file
DSDavid B Sacks
David B Sacks
MAMark Arnold
Mark Arnold
GBGeorge Bakris
George Bakris
DBDavid E. Bruns
David E. Bruns
AHAndrea R. Horvath
Andrea R. Horvath
MKM. Sue Kirkman
M. Sue Kirkman
BACKGROUND: Numerous laboratory tests are used in the diagnosis and management of diabetes mellitus. The quality of the scientific evidence supporting the use of these assays varies substantially. APPROACH: An expert committee compiled evidence-based recommendations for laboratory analysis in screening, diagnosis, or monitoring of diabetes. The overall quality of the evidence and the strength of the recommendations were evaluated. The draft consensus recommendations were evaluated by invited reviewers and presented for public comment. Suggestions were incorporated as deemed appropriate by the authors (see Acknowledgments). The guidelines were reviewed by the Evidence Based Laboratory Medicine Committee and the Board of Directors of the American Association for Clinical Chemistry and by the Professional Practice Committee of the American Diabetes Association. CONTENT: Diabetes can be diagnosed by demonstrating increased concentrations of glucose in venous plasma or increased hemoglobin A1c (HbA1c) in the blood. Glycemic control is monitored by the people with diabetes measuring their own blood glucose with meters and/or with continuous interstitial glucose monitoring (CGM) devices and also by laboratory analysis of HbA1c. The potential roles of noninvasive glucose monitoring, genetic testing, and measurement of ketones, autoantibodies, urine albumin, insulin, proinsulin, and C-peptide are addressed. SUMMARY: The guidelines provide specific recommendations based on published data or derived from expert consensus. Several analytes are found to have minimal clinical value at the present time, and measurement of them is not recommended.

1 June 2010 in The Lancet
Verified
Journal Article
Closed access
ARAndrew Renehan
Andrew Renehan
USUlf Smith
Ulf Smith
MKM Sue Kirkman
M Sue Kirkman

29 March 2024 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
DSDavid B Sacks
David B Sacks
MKM. Sue Kirkman
M. Sue Kirkman
RLRandie R. Little
Randie R. Little
Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization of A1C testing was achieved, leading to high-quality results in clinical laboratories. We address the use of POC A1C testing in clinical situations and summarize the advantages and disadvantages of POC A1C testing. We emphasize the importance of considering the limitations of these devices and following correct testing procedures to ensure that accurate A1C results are obtained for optimal care of patients.

20 July 2023 in Diabetes Care
Verified
Journal Article
Open access
PDF file
DSDavid B Sacks
David B Sacks
MAMark Arnold
Mark Arnold
GBGeorge Bakris
George Bakris
DBDavid E. Bruns
David E. Bruns
AHAndrea R. Horvath
Andrea R. Horvath
MKM. Sue Kirkman
M. Sue Kirkman
BACKGROUND: Numerous laboratory tests are used in the diagnosis and management of patients with diabetes mellitus. The quality of the scientific evidence supporting the use of these assays varies substantially. An expert committee compiled evidence-based recommendations for laboratory analysis in patients with diabetes. The overall quality of the evidence and the strength of the recommendations were evaluated. The draft consensus recommendations were evaluated by invited reviewers and presented for public comment. Suggestions were incorporated as deemed appropriate by the authors (see Acknowledgments in the full version of the guideline). The guidelines were reviewed by the Evidence Based Laboratory Medicine Committee and the Board of Directors of the American Association for Clinical Chemistry and by the Professional Practice Committee of the American Diabetes Association. CONTENT: Diabetes can be diagnosed by demonstrating increased concentrations of glucose in venous plasma or increased hemoglobin A1c (HbA1c) in the blood. Glycemic control is monitored by the patients measuring their own blood glucose with meters and/or with continuous interstitial glucose monitoring devices and also by laboratory analysis of HbA1c. The potential roles of noninvasive glucose monitoring; genetic testing; and measurement of ketones, autoantibodies, urine albumin, insulin, proinsulin, and C-peptide are addressed. SUMMARY: The guidelines provide specific recommendations based on published data or derived from expert consensus. Several analytes are found to have minimal clinical value at the present time, and measurement of them is not recommended.

21 November 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
DIDaria Igudesman
Daria Igudesman
JCJamie Crandell
Jamie Crandell
KCKaren D. Corbin
Karen D. Corbin
DZDessi Zaharieva
Dessi Zaharieva
AAAnanta Addala
Ananta Addala
FGfor the ACTION Study Group
for the ACTION Study Group